Should Onglyza, Zemiglo and Nesian be happy or sad on the decision?
The second type diabetes treatments of the DPP-4 inhibitor type,‘Onglyza’(generic name: saxagliptin), ‘Zemiglo’ (generic name: gemigliptin) and‘Nesian’ (generic name: alogliptin), have stuck in a ambiguous situation.
Although the criteria of the National Health Insurance benefits on DPP-4 inhibi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
